Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection
Johannes Wedel, … , Diane R. Bielenberg, David M. Briscoe
Johannes Wedel, … , Diane R. Bielenberg, David M. Briscoe
Published July 1, 2025
Citation Information: J Clin Invest. 2025;135(13):e172218. https://doi.org/10.1172/JCI172218.
View: Text | PDF
Research Article Immunology

Neuropilin-2 functions as a coinhibitory receptor to regulate antigen-induced inflammation and allograft rejection

  • Text
  • PDF
Abstract

Coinhibitory receptors function as central modulators of the immune response to resolve T effector activation and/or to sustain immune homeostasis. Here, using humanized SCID mice, we found that neuropilin–2 (NRP2) is inducible on late effector and exhausted subsets of human CD4+ T cells and that it is coexpressed with established coinhibitory molecules including PD-1, CTLA4, TIGIT, LAG3, and TIM3. In murine models, we also found that NRP2 is expressed on effector memory CD4+ T cells with an exhausted phenotype and that it functions as a key coinhibitory molecule. Knockout (KO) of NRP2 resulted in hyperactive CD4+ T cell responses and enhanced inflammation in delayed-type hypersensitivity and transplantation models. After cardiac transplantation, allograft rejection and graft failure were accelerated in global as well as CD4+ T cell–specific KO recipients, and enhanced alloimmunity was dependent on NRP2 expression on CD4+ T effectors but not on CD4+Foxp3+ Tregs. Also, KO Tregs were found to be as efficient as WT cells in the suppression of effector responses in vitro and in vivo. These collective findings identify NRP2 as a potentially novel coinhibitory receptor and demonstrate that its expression on CD4+ T effector cells is of great functional importance in immunity.

Authors

Johannes Wedel, Nora Kochupurakkal, Sek Won Kong, Sayantan Bose, Ji-Won Lee, Madeline Maslyar, Bayan Alsairafi, Kayla MacLeod, Kaifeng Liu, Hengcheng Zhang, Masaki Komatsu, Hironao Nakayama, Diane R. Bielenberg, David M. Briscoe

×

Figure 6

NRP2 expression on CD4+ T effector cells is required for long-term allograft survival.

Options: View larger image (or click on image) Download as PowerPoint
NRP2 expression on CD4+ T effector cells is required for long-term allog...
(A–F) Single MHC class II mismatched B6.C-H-2bm12 donor hearts were transplanted into NRP2 transgenic mice on the C57BL/6 background and graft function was monitored by palpation of the heartbeat. (A) Kaplan-Meier graft survival curves after transplantation of B6.C-H-2bm12 heart allografts into WT, NRP2–/–, or ΔNRP2-CD4-KO recipients. (B) Histology as evaluated by H&E staining of allografts harvested on day 14 after transplantation. (C) CD4+ T cell priming in WT and ΔNRP2-CD4-KO mice as evaluated by IFN-γ ELISPOT on day 14 after transplantation (mean spots/well ± SD; Mann-Whitney U test). (D and E) Allograft survival after transplantation of B6.C-H-2bm12 hearts into CD8-depleted ΔNRP2-CD4-KO or NRP2lox/lox recipients. (E) Efficiency of CD8 depletion from splenocytes by anti-CD8 treatment peri-transplant by flow cytometry on day 2 after transplantation. (F) Kaplan-Meier survival curves after transplantation of B6.C-H-2bm12 cardiac allografts into C57BL/6 NRP2lox/lox, ΔNRP2-CD4, Foxp3-Cre, or ΔNRP2-Foxp3-KO recipients. (G–I) C57BL/6 NRP2lox/lox and ΔNRP2-CD4-KO mice received a fully MHC-mismatched Balb/c skin transplant; Teffs and Tregs were harvested on day 14, and Treg function was assessed in an in vitro suppression assay. (G and H) A representative Treg suppression assay showing proliferation of NRP2 WT (G) or KO (H) Teff responders without Tregs (left panels) or with increasing ratios of Tregs (right panels). (I) Bar graph summarizing 5 independent assays comparing the percentage of suppressive activity of NRP2lox/lox and ΔNRP2-CD4-KO Tregs (mean ± SD, 1-way ANOVA with Tukey’s multiple-comparison test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts